Inequities in access to targeted cancer treatments are due to the high costs of tests, limited number of approved medicines or clinical trials and poor communication with patients, as two new surveys report
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
PROs encourage patient-centred cancer care
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.